TRIANGLE operation, combined with adequate adjuvant chemotherapy, can improve the prognosis of pancreatic head cancer: A retrospective study

Table 2 Surgical and recurrence data

Variables	PDTRIANGLE (n = 52)	PDnon-TRIANGLE (n = 55)	P value
Operative time, median (IQR; min)	386 (324-423)	390 (345-425)	0.527
Intraoperative blood loss, median (IQR; mL)	300 (200-500)	300 (200-500)	0.863
LOS, median (IQR)	14 (11-19)	15 (12-22)	0.177
ICU stay ≥ 2 d	13 (25.0)	17 (30.9)	0.496
POPF (B/C)	9 (17.3)	13 (23.6)	0.418
Bile leakage (B/C)	0 (0.0)	3 (5.5)	0.262
Chyle leak (B/C)	0 (0.0)	2 (3.6)	0.496
DGE (B/C)	3 (5.8)	5 (9.1)	0.775
PPH (B/C)	0 (0.0)	2 (3.6)	0.496
Intra-abdominal infection	10 (19.2)	9 (16.4)	0.698
Diarrhea	14 (26.9)	9 (16.4)	0.184
Reoperation	1 (1.9)	3 (5.5)	0.651
90-d mortality	0 (0.0)	0 (0.0)	1.000
Adjuvant chemotherapy, ≥ 6 months	30 (57.7)	27 (49.1)	0.373
Chemotherapy regimens1			0.887
Gemcitabine-based	24 (80.0)	22 (81.5)
5-fluorouracil-based	6 (20.0)	5 (18.5)
Recurrence			< 0.001a
Yes	25 (48.1)	45 (81.8)
No	27 (51.9)	10 (18.2)

^aP < 0.001.

¹Variables calculated on the total of patients who received adjuvant chemotherapy lasting longer than 6 months Values in parentheses are percentages unless indicated otherwise.

PD: Pancreaticoduodenectomy; IQR: Interquartile range; ICU: Intensive care unit; LOS: Length of stay; POPF: Postoperative pancreatic fistula; DGE: Delayed gastric emptying; PPH: Postpancreatectomy hemorrhage.